About Edwards Lifesciences Corporation
https://www.edwards.comEdwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
CEO
Bernard J. Zovighian
Compensation Summary
(Year 2024)
Salary $1,133,846
Stock Awards $6,147,250
Option Awards $5,748,762
Incentive Plan Pay $1,451,588
All Other Compensation $98,028
Total Compensation $14,579,474
Industry Medical - Devices
Sector Healthcare
Went public March 27, 2000
Method of going public IPO
Full time employees 15,800
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-06-01 | Forward | 3:1 |
| 2015-12-14 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Total 792
Showing Top 3 of 792
Ratings Snapshot
Rating : A-
Discounted Cash Flow 4
Return On Equity 4
Return On Assets 5
Debt To Equity 3
Price To Earnings 2
Price To Book 2
Overall Score 4
Most Recent Analyst Grades
Grade Summary
Buy 6
Outperform 3
Overweight 4
Equal Weight 1
Perform 1
Peer Perform 1
Neutral 2
Hold 2
Showing Top 6 of 20
Price Target
Target High $105
Target Low $87
Target Median $96
Target Consensus $96.2
Institutional Ownership
VANGUARD GROUP INC
Shares:70.36M
Value:$5.85B
BLACKROCK, INC.
Shares:54.29M
Value:$4.51B
BLACKROCK INC.
Shares:50.98M
Value:$4.24B
Summary
% Of Shares Owned 63.73%
Total Number Of Holders 1,677
Showing Top 3 of 1,677
Market Cap $49.66 B
52w High $87.89
52w Low $65.94
P/E 36.45
Volume 3.17M
Outstanding Shares 587.15M
About Edwards Lifesciences Corporation
https://www.edwards.comEdwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.55B ▲ | $784.5M ▲ | $291.1M ▼ | 18.74% ▼ | $0.5 ▼ | $387.6M ▼ |
| Q2-2025 | $1.53B ▲ | $758.7M ▲ | $329.8M ▼ | 21.52% ▼ | $0.57 ▼ | $400.2M ▼ |
| Q1-2025 | $1.41B ▲ | $716.3M ▼ | $358M ▼ | 25.34% ▼ | $0.61 ▼ | $470.5M ▼ |
| Q4-2024 | $1.39B ▲ | $781M ▲ | $385.6M ▼ | 27.83% ▼ | $0.65 ▼ | $483.7M ▲ |
| Q3-2024 | $1.35B | $740.9M | $3.07B | 226.73% | $5.14 | $428.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.84B ▼ | $13.27B ▼ | $3.07B ▲ | $10.21B ▼ |
| Q2-2025 | $4.06B ▲ | $13.49B ▲ | $2.88B ▲ | $10.55B ▲ |
| Q1-2025 | $3.9B ▼ | $13.02B ▼ | $2.83B ▼ | $10.13B ▲ |
| Q4-2024 | $3.98B ▼ | $13.06B ▲ | $2.99B ▼ | $10B ▲ |
| Q3-2024 | $4.45B | $12.97B | $3.36B | $9.55B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $290.3M ▼ | $573.7M ▲ | $-427.8M ▼ | $-740.1M ▼ | $-595.2M ▼ | $516.2M ▲ |
| Q2-2025 | $331.5M ▼ | $290.2M ▲ | $-172.1M ▼ | $52.7M ▲ | $141.2M ▲ | $240.9M ▲ |
| Q1-2025 | $356.4M ▼ | $280.4M ▲ | $85.3M ▲ | $-258M ▼ | $90M ▲ | $224.4M ▲ |
| Q4-2024 | $385.6M ▼ | $-127.5M ▼ | $-576.7M ▼ | $28.6M ▲ | $-624.6M ▼ | $-177.3M ▼ |
| Q3-2024 | $3.07B | $351.8M | $2.7B | $-976.7M | $2.04B | $319.9M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Surgical Heart Valve Therapy | $210.00M ▲ | $250.00M ▲ | $270.00M ▲ | $260.00M ▼ |
 Transcatheter Heart Valves | $1.04Bn ▲ | $1.05Bn ▲ | $1.13Bn ▲ | $1.15Bn ▲ |
 Transcatheter Mitral And Tricuspid Therapies | $110.00M ▲ | $120.00M ▲ | $130.00M ▲ | $150.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 Europe | $300.00M ▲ | $380.00M ▲ | $390.00M ▲ | $340.00M ▼ |
 JAPAN | $60.00M ▲ | $100.00M ▲ | $90.00M ▼ | $80.00M ▼ |
 Rest of World | $100.00M ▲ | $170.00M ▲ | $0 ▼ | $150.00M ▲ |
 UNITED STATES | $640.00M ▲ | $890.00M ▲ | $910.00M ▲ | $840.00M ▼ |
CEO
Bernard J. Zovighian
Compensation Summary
(Year 2024)
Salary $1,133,846
Stock Awards $6,147,250
Option Awards $5,748,762
Incentive Plan Pay $1,451,588
All Other Compensation $98,028
Total Compensation $14,579,474
Industry Medical - Devices
Sector Healthcare
Went public March 27, 2000
Method of going public IPO
Full time employees 15,800
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-06-01 | Forward | 3:1 |
| 2015-12-14 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Total 792
Showing Top 3 of 792
Ratings Snapshot
Rating : A-
Discounted Cash Flow 4
Return On Equity 4
Return On Assets 5
Debt To Equity 3
Price To Earnings 2
Price To Book 2
Overall Score 4
Most Recent Analyst Grades
Grade Summary
Buy 6
Outperform 3
Overweight 4
Equal Weight 1
Perform 1
Peer Perform 1
Neutral 2
Hold 2
Showing Top 6 of 20
Price Target
Target High $105
Target Low $87
Target Median $96
Target Consensus $96.2
Institutional Ownership
VANGUARD GROUP INC
Shares:70.36M
Value:$5.85B
BLACKROCK, INC.
Shares:54.29M
Value:$4.51B
BLACKROCK INC.
Shares:50.98M
Value:$4.24B
Summary
% Of Shares Owned 63.73%
Total Number Of Holders 1,677
Showing Top 3 of 1,677